From Yahoo Finance: 2025-05-26 22:57:00

Y-mAbs Therapeutics, Inc. (YMAB) presents early-stage clinical data from GD2-SADA PRIT trial at ANR Meeting. Trial 1001 shows promising results in Phase 1 study for high-risk neuroblastoma and GD2-expressing tumors.

Focus on radioimmunotherapy innovation with GD2-SADA construct. Trial 1001 completes Part A, identifies optimal dosage for GD2-SADA protein. Data readout scheduled for virtual R&D update on May 28.

YMAB stock rises 5.37% prior to data unveiling, reflecting investor confidence. Analysts offer Buy rating with $16.50 price target, predicting 281.94% upside potential.

Investment potential in YMAB acknowledged, but emphasis on AI stocks for higher returns with limited downside risk. Check out report on cheapest AI stock for 100x upside potential.



Read more at Yahoo Finance: Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025